G Curigliano1, D Disalvatore2, A Esposito3, G Pruneri4, M Lazzeroni5, A Guerrieri-Gonzaga5, A Luini6, R Orecchia7, A Goldhirsch8, N Rotmensz2, B Bonanni5, G Viale4. 1. Division of Experimental Therapeutics giuseppe.curigliano@ieo.it. 2. Division of Epidemiology and Biostatistics. 3. Division of Experimental Therapeutics. 4. Department of Pathology and Laboratory Medicine School of Medicine, University of Milano, Milan. 5. Division of Cancer Prevention and Genetics. 6. Division of Senology. 7. School of Medicine, University of Milano, Milan Department of Medical Imaging and Radiation Sciences. 8. Breast Health Program, European Institute of Oncology, Milan, Italy.
Abstract
BACKGROUND: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexpression in patients with ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: We identified patients with HER2-positive DCIS among a population of 1667 cases, prospectively diagnosed and surgically treated at the European Institute of Oncology from 1996 to 2008. Rates of subsequent DCIS or invasive cancer in HER2-positive disease were estimated. We evaluated Cumulative Incidence of In Situ Breast Cancer Recurrence (isBCR), INvasive Breast Cancer Recurrence (IBCR) and any Breast Cancer Recurrence (BCR). isBCR, IBCR and BCR were defined as the time from surgery to breast cancer recurrence as first event (in situ, invasive or both, respectively) or last visit in case of no events. RESULTS: We identified 560 (33.5%) patients with HER2-positive DCIS. The median follow-up was 7.6 years (interquartile range 5.9-9.5). We observed 422 events out of 1667 patients, with 141 in situ recurrences, 201 invasive recurrences and 80 other events (64 second primaries and 16 deaths). The 10-year isBCR proportions were 11.8% [95% confidence interval (CI) 9.0% to 15.4%] in the HER2-positive group and 8.8% (95% CI 6.9% to 11.0%) in the HER2-negative group (Gray test, P = 0.010). At multivariable analysis, the adjusted risk of isBCR was higher in the HER2-positive group than in the HER2-negative group [hazard ratio (HR) HER2 positive versus negative: 1.59 (95% CI 1.06-2.39)]. We observed significant differences both in BCR and isBCR for patients treated by quadrantectomy without radiotherapy versus patients treated with radiotherapy [adjusted HR HER2 positive versus negative: 1.53 (95% CI 1.07-2.18) and adjusted HR HER2 positive versus negative: 2.18 (95% CI 2.18-3.69), respectively]. CONCLUSION: HER2 overexpression predicts an increased risk of isBCR. Radiotherapy reduces local failure rates in HER2-positive DCIS.
BACKGROUND: To assess the prognostic role of human epidermal growth factor receptor 2 (HER2) overexpression in patients with ductal carcinoma in situ (DCIS). PATIENTS AND METHODS: We identified patients with HER2-positive DCIS among a population of 1667 cases, prospectively diagnosed and surgically treated at the European Institute of Oncology from 1996 to 2008. Rates of subsequent DCIS or invasive cancer in HER2-positive disease were estimated. We evaluated Cumulative Incidence of In Situ Breast Cancer Recurrence (isBCR), INvasive Breast Cancer Recurrence (IBCR) and any Breast Cancer Recurrence (BCR). isBCR, IBCR and BCR were defined as the time from surgery to breast cancer recurrence as first event (in situ, invasive or both, respectively) or last visit in case of no events. RESULTS: We identified 560 (33.5%) patients with HER2-positive DCIS. The median follow-up was 7.6 years (interquartile range 5.9-9.5). We observed 422 events out of 1667 patients, with 141 in situ recurrences, 201 invasive recurrences and 80 other events (64 second primaries and 16 deaths). The 10-year isBCR proportions were 11.8% [95% confidence interval (CI) 9.0% to 15.4%] in the HER2-positive group and 8.8% (95% CI 6.9% to 11.0%) in the HER2-negative group (Gray test, P = 0.010). At multivariable analysis, the adjusted risk of isBCR was higher in the HER2-positive group than in the HER2-negative group [hazard ratio (HR) HER2 positive versus negative: 1.59 (95% CI 1.06-2.39)]. We observed significant differences both in BCR and isBCR for patients treated by quadrantectomy without radiotherapy versus patients treated with radiotherapy [adjusted HR HER2 positive versus negative: 1.53 (95% CI 1.07-2.18) and adjusted HR HER2 positive versus negative: 2.18 (95% CI 2.18-3.69), respectively]. CONCLUSION:HER2 overexpression predicts an increased risk of isBCR. Radiotherapy reduces local failure rates in HER2-positive DCIS.
Authors: Megan E Tesch; Shoshana M Rosenberg; Laura C Collins; Julia S Wong; Laura Dominici; Kathryn J Ruddy; Rulla Tamimi; Lidia Schapira; Virginia F Borges; Ellen Warner; Steven E Come; Ann H Partridge Journal: Ann Surg Oncol Date: 2022-08-12 Impact factor: 4.339
Authors: Mangesh A Thorat; Pauline M Levey; J Louise Jones; Sarah E Pinder; Nigel J Bundred; Ian S Fentiman; Jack Cuzick Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531
Authors: Mieke R Van Bockstal; Marie C Agahozo; Linetta B Koppert; Carolien H M van Deurzen Journal: Int J Cancer Date: 2019-05-08 Impact factor: 7.396
Authors: Mangesh A Thorat; Pauline M Levey; J Louise Jones; Sarah E Pinder; Nigel J Bundred; Ian S Fentiman; Jack Cuzick Journal: Clin Cancer Res Date: 2021-03-16 Impact factor: 12.531
Authors: Shusma C Doebar; Esther C van den Broek; Linetta B Koppert; Agnes Jager; Margreet H A Baaijens; Inge-Marie A M Obdeijn; Carolien H M van Deurzen Journal: Breast Cancer Res Treat Date: 2016-06-18 Impact factor: 4.872